GeoVax Labs, Inc. (GOVX)
Stock Price:
$2.90 USD
0.22 (8.21%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $2.88 -0.02 (-0.69%) Nov 30, 7:51 PM
Key Info
| Market Cap |
11.05M |
| Revenue (ttm) |
1.84M |
| Net Income (ttm) |
-2.21M |
| Shares Out |
3.81M |
| EPS (ttm) |
-1.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$2.90 |
| Previous Close |
$2.68 |
| Change ($) |
0.22 |
| Change (%) |
8.21% |
| Day's Open |
2.81 |
| Day's Range |
2.70 - 2.95 |
| Day's Volume |
840,982 |
| 52-Week Range |
2.63 - 3.65 |
More Stats
| Market Cap |
11.05M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
3.81M |
| Float |
n/a |
| EPS (basic) |
14,011.64 |
| EPS (diluted) |
-1.84 |
| FCF / Share |
-1.91 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
29,075 |
| Short Ratio |
0.00 |
| Short % of Float |
n/a |
| Beta |
1.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.00 |
| PB Ratio |
1.02 |
| Revenue |
1.84M |
| Operating Income |
-2.07M |
| Net Income |
-2.21M |
| Free Cash Flow |
-1.50M |
| Net Cash |
11.39M |
| Net Cash / Share |
2.99 |
| Gross Margin |
-48.10% |
| Operating Margin |
-112.51% |
| Profit Margin |
-120.20% |
| FCF Margin |
-81.24% |
| ROA |
-217.33% |
| ROE |
n/a |
| ROIC |
131.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
8.00
Current: $2.90
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.18 | 0.96 | 1.08 | 0.83 | 0.43 | 0.88 | 2.42 | 2.66 | 4.90 | 5.19 |
| Revenue Growth | 22.08% | -10.42% | 29.72% | 93.64% | -51.52% | -63.48% | -9.02% | -45.77% | -5.5% | - |
| Gross Profit | 1.18 | 0.96 | 1.08 | 0.83 | 0.43 | 0.88 | 2.42 | 2.66 | 4.90 | 5.19 |
| Operating Income | -2.37 | -2.56 | -2.17 | -3.27 | -2.69 | -2.74 | -2.29 | -2.14 | -2.35 | -2.77 |
| Net Income | -2.37 | -2.56 | -2.17 | -3.27 | -2.69 | -2.73 | -2.28 | -2.14 | -2.35 | -2.75 |
| Shares Outstanding | 3.02 | 0.01 | - | - | - | - | - | - | - | - |
| Earnings Per Share | -785.00 | -312,206.60 | -600,000.00 | -1,600,000.00 | -1,600,000.00 | -2,000,000.00 | -2,200,000.00 | -2,400,000.00 | -3,000,000.00 | -3,600,000.00 |
| Operating Cash Flow | -1.40 | -1.54 | -1.69 | -1.95 | -2.71 | -2.25 | -1.69 | -2.44 | -0.30 | -2.44 |
| Capital Expenditures | -0.01 | - | - | - | -0.02 | -0.04 | -0.09 | - | -0.01 | - |
| Free Cash Flow | -1.41 | -1.54 | -1.69 | -1.95 | -2.72 | -2.29 | -1.78 | -2.44 | -0.32 | -2.44 |
| Cash & Equivalents | 0.29 | 0.27 | 0.32 | 0.47 | 1.06 | 1.10 | 2.51 | 1.04 | 1.17 | 1.08 |
| Total Debt | 0.04 | 0.30 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 0.25 | -0.03 | 0.32 | 0.47 | 1.06 | 1.10 | 2.51 | 1.04 | 1.17 | 1.08 |
| Assets | 0.47 | 0.64 | 0.49 | 0.61 | 1.33 | 1.33 | 2.84 | 1.48 | 1.65 | 2.36 |
| Liabilities | 2.04 | 1.66 | 0.81 | 0.37 | 0.13 | 0.19 | 0.31 | 0.33 | 0.94 | 0.52 |
| Book Value | -1.57 | -1.02 | -0.32 | 0.24 | 1.20 | 1.15 | 2.53 | 1.15 | 0.70 | 1.84 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
GeoVax Labs, Inc. |
| Country |
United States |
| Employees |
6 |
| CEO |
David A. Dodd |
Stock Information
| Ticker Symbol |
GOVX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GOVX |
Description
GeoVax Labs, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.